Aclaris Accounts Payable from 2010 to 2025

ACRS Stock  USD 2.48  0.09  3.77%   
Aclaris Therapeutics Accounts Payable yearly trend continues to be comparatively stable with very little volatility. Accounts Payable will likely drop to about 7.2 M in 2025. Accounts Payable is the amount Aclaris Therapeutics owes to suppliers or vendors for products or services received but not yet paid for. It represents Aclaris Therapeutics' short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2013-12-31
Previous Quarter
7.3 M
Current Value
7.7 M
Quarterly Volatility
4.3 M
 
Yuan Drop
 
Covid
Check Aclaris Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aclaris Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 942.8 K, Interest Expense of 3.2 M or Selling General Administrative of 21.3 M, as well as many indicators such as Price To Sales Ratio of 2.56, Dividend Yield of 0.0 or PTB Ratio of 0.67. Aclaris financial statements analysis is a perfect complement when working with Aclaris Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Aclaris Therapeutics Correlation against competitors.
For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.

Latest Aclaris Therapeutics' Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Aclaris Therapeutics over the last few years. An accounting item on the balance sheet that represents Aclaris Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Aclaris Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Aclaris Therapeutics' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aclaris Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

Aclaris Accounts Payable Regression Statistics

Arithmetic Mean5,670,312
Geometric Mean2,844,703
Coefficient Of Variation84.37
Mean Deviation4,222,312
Median7,223,300
Standard Deviation4,784,183
Sample Variance22.9T
Range14.4M
R-Value0.77
Mean Square Error10T
R-Squared0.59
Significance0.0005
Slope774,076
Total Sum of Squares343.3T

Aclaris Accounts Payable History

20257.2 M
202410.2 M
20238.9 M
202210.4 M
202110 M
20205.3 M
20199.9 M

About Aclaris Therapeutics Financial Statements

Aclaris Therapeutics shareholders use historical fundamental indicators, such as Accounts Payable, to determine how well the company is positioned to perform in the future. Although Aclaris Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Aclaris Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Aclaris Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Accounts Payable10.2 M7.2 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Aclaris Stock Analysis

When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.